Clinical trial

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

NCT06399835

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-02-01

PhasePHASE4

Study timeline

Study start (actual)2024-02-01Date precision: day

Registry last updated2026-05-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

EnavogliflozinDRUG

PioglitazoneDRUG · verified · RxNorm: pioglitazone

Sponsors & collaborators

Seoul National University Bundang Hospitallead sponsor

Daewoong Pharmaceutical Co. LTD.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06399835 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.